owkin aims to complement everyday clinical practice with its tool.d the company's working on an updated version for those in the uk. what does an oncologist who's used to having difficult conversations with patients make of it, though? what we do now, in terms of assessment of the risk, is to have the standard information, the standard clinical— and histopathological information. that are the tumour size, - the lymph—node involvement, the tumour grade, the tumour histology, the expression- of their oestrogen. the ai is going to provide a more comprehensive i analysis of all this data, - and it's going to complement these genomic tests, . these genomic analyses. pathologists here aim to digitise and analyse another 400 slides over the next two years, as part of the prospective validation stage of the relapse—risk study. to look at the patient�*s breast cancer tissue, the pathologist places the sample onto a slide, and then embeds it in paraffin wax. this helps both preserve it and keep it in place. then, instead of it being put under a microscope, it'

owkin aims to complement everyday clinical practice with its tool.n updated version for those in the uk. what does an oncologist, who's used to having difficult conversations with patients, make of it, though? what we do now in terms of assessment of the risk is to have the standard information, the standard clinical— and histopathological information — that are the tumour size, _ the lymph—node involvement, j the tumour grade, the tumour histology, the expression of the oestrogen. - the ai is going to provide a more comprehensive i analysis of all this data, - and it's going to complement these genomic tests, | this genomic analysis. pathologists here aim to digitise and analyse another a00 slides over the next two years as part of the prospective validation stage of the relapse—risk study. to look at the patient�*s breast cancer tissue, the pathologist places the sample onto a slide and then embeds it in paraffin wax. this helps both preserve it and keep it in place. then, instead of it being put under a microscope, it's taken from the lab to a dig

owkin aims to complement everyday clinical practice with its tool.ides over the next two years as part of the prospective validation stage of the relapse—risk study. to look at the patient�*s breast cancer tissue, the pathologist places the sample onto a slide, and then embeds it in paraffin wax. this helps both preserve it and keep it in place. then, instead of it being put under a microscope, it's taken from the lab to a digital scanner, where a very high—resolution image of the cancerous cells is created. digitising slides isn't a new concept, but running an ai model to determine the risk of cancer returning is. no—one involved is suggesting that this will replace the importance of doctors, but the hope is that more detailed data and analysis could enhance theirjudgement calls. within minutes of the slides being scanned, the ai will have made its assessment of the risk. in this case, it's low, but when it's at a more moderate level, the dilemma really exists. sometimes there is a grey zone and some cases are borderline, so maybe not completely goo